Researchers study 'ACT TIL' approach to treating metastatic melanoma

October 17, 2012

Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL). Tumor tissues were surgically removed from patients, minced and grown in culture. The treatment combined chemotherapy, then ACT with TIL, followed by interleukin-2 (IL-2). The combination therapy drew a high response rate from some patients.

The study appears in the October issue of the Journal of .

"Our purpose was to demonstrate the feasibility of performing TIL growth and the efficacy of ACT TIL therapy using techniques developed at the ," said Amod Sarnaik, M.D., assistant member of the Cutaneous Oncology Department at Moffitt. "Combining chemotherapy with ACT and high dose IL-2 resulted in a 38 percent objective response rate in patients with metastatic melanoma."

"Although our clinical study successfully met its goal of demonstrating that ACT TIL therapy could be offered to advanced melanoma patients, strategies to improve on its feasibility and efficacy are under way," said Shari A. Pilon-Thomas, Ph.D., assistant member of the Immunology Program at Moffitt. "Combination therapies that enhance the proliferation and function of TIL are being explored."

Explore further: Tumor-Infiltrating lymphocyte grade IDs melanoma survival

More information: journals.lww.com/immunotherapy … l_Transfer_of.4.aspx

A second-generation ACT TIL trial is enrolling patients at Moffitt. For more, patients can go to the trial website or call Moffitt at 813-745-4279.

Related Stories

Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012
(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a ...

Combination therapy delivers one-two punch to skin cancer, boosting anti-tumor activity

August 16, 2012
(Medical Xpress) -- Treating metastatic melanoma by combining immunotherapy with a drug that inhibits the cancer-spreading activity of a common gene mutation significantly increased survival times in an animal model, according ...

Researchers study effect of chemotherapy combined with immunotherapy for advanced cancers

October 9, 2012
Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and Tianjin Medical University Cancer Institute and Hospital in China have discovered that combining chemotherapy drugs and immunotherapy ...

Response rate high for some patients with metastatic melanoma treated with vemurafenib

March 16, 2012
An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase ...

Immunotherapy and chemotherapy regimen may prolong survival in advanced cancers

April 3, 2012
Maintenance therapy with interleukin-2 and 13-cis retinoic acid may be an inexpensive method for increasing survival in patients with a variety of stage 4 cancers, according to data reported at the AACR Annual Meeting 2012, ...

Recommended for you

The skinny on lipid immunology

October 20, 2017
Phospholipids - fat molecules that form the membranes found around cells - make up almost half of the dry weight of cells, but when it comes to autoimmune diseases, their role has largely been overlooked. Recent research ...

Bacterial pathogens outwit host immune defences via stealth mechanisms

October 20, 2017
Despite their relatively small genome in comparison to other bacteria, mycoplasmas can cause persistent and often difficult-to-treat infections in humans and animals. An extensive study by researchers from Vetmeduni Vienna ...

Scientists find where HIV 'hides' to evade detection by the immune system

October 19, 2017
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human ...

Tracing cell death pathway points to drug targets for brain damage, kidney injury, asthma

October 19, 2017
University of Pittsburgh scientists are unlocking the complexities of a recently discovered cell death process that plays a key role in health and disease, and new findings link their discovery to asthma, kidney injury and ...

Researchers release the brakes on the immune system

October 18, 2017
Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural "brakes" in the immune defense mechanism that normally prevent an excessive immune response. Researchers at the ...

How cytoplasmic DNA triggers inflammation in human cells

October 17, 2017
A team led by LMU's Veit Hornung has elucidated the mechanism by which human cells induce inflammation upon detection of cytoplasmic DNA. Notably, the signal network involved differs from that used in the same context in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.